These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25841722)

  • 21. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
    Rini BI; Quinn DI; Baum M; Wood LS; Tarazi J; Rosbrook B; Arruda LS; Cisar L; Roberts WG; Kim S; Motzer RJ
    Target Oncol; 2015 Mar; 10(1):45-53. PubMed ID: 24595903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
    Umeyama Y; Shibasaki Y; Akaza H
    Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urological cancer: second-line option for metastatic RCC.
    Marchesi V
    Nat Rev Clin Oncol; 2013 Jun; 10(6):305. PubMed ID: 23629471
    [No Abstract]   [Full Text] [Related]  

  • 27. Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?
    Iacovelli R; Verzoni E; De Braud FM; Procopio G
    Cancer Biol Ther; 2014 May; 15(5):486-8. PubMed ID: 24556857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
    Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
    Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axitinib controlled metastatic renal cell carcinoma for 5 years.
    Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S
    Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
    Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A
    Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
    Dranitsaris G; Schmitz S; Broom RJ
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axitinib: in advanced, treatment-experienced renal cell carcinoma.
    Yang LP; McKeage K
    Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of axitinib through a probabilistic decision model.
    Petrou P
    Expert Opin Pharmacother; 2015 Jun; 16(8):1233-43. PubMed ID: 25958963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axitinib for renal cell carcinoma.
    Sonpavde G; Hutson TE; Rini BI
    Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
    Larkin J; Paine A; Tumur I; Cappelleri JC; Healey PJ; Foley G; Mitchell S; Kroes M; Chen C
    Expert Opin Pharmacother; 2013 Jan; 14(1):27-39. PubMed ID: 23256638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.